

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/535,000
				Filing Date	May 16, 2005
				First Named Inventor	Masakazu HATANO
				Group Art Unit	1617
				Examiner Name	Gigi Georgiana HUANG
Sheet	1	of	3	Attorney Docket Number	05318/HG

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number	Kind Code	Patentee or Applicant	Publication Date (MM-DD-YYYY)
	1	2005/0043412	A1	ICHIKAWA et al.	02-24-2005

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Country Code	Document Number	Kind Code	Patentee or Applicant	Publication Date (MM-DD-YYYY)	Translation	
							Yes	Abstract Only
	2	WO	95/28387	A1	YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.	10-26-1995	a	
	3	EP	0 757 038	A1	YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.	02-05-1997		
	4	JP	2004-513148	A	PHARMACIA AB	04-30-2004	b	
	5	WO	02/38158	A1	PHARMACIA AB	05-16-2002		
	6	JP	63-79828	A	LABORATORIES MERCK, SHARP & DOHME	05-16-2002	c	
	7	EP	0 253 717	A1	LABORATORIES MERCK, SHARP & DOHME	01-20-1988		

OTHER DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	8	Kyle A. PARROW et al., "Is It Worthwhile to Add Dipivefrin HC1 0.1% to Topical β_1 , β_2 -blocker Therapy?", <u>Ophthalmology</u> , 96(9), 1338-1342 (1989).
	9	Mark B. ABELSON et al., "Sustained Reduction of Intraocular Pressure in Humans With the Calcium Channel Blocker Verapamil," <u>American Journal of Ophthalmology</u> , 105(2), 155-159 (1988).
	10	Kristine A. ERICKSON et al., "Verapamil Increases Outflow Facility in the Human Eye," <u>Exp. Eye Res.</u> , 61(5), 565-567 (1995).

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE MAILED OR TRANSMITTED: April 15, 2011

a EP 0 757 038 IS A RELATED FAMILY MEMBER OF WO 95/28387.

b WO 02/38158 IS A RELATED FAMILY MEMBER OF JP 2004-513148.

c EP 0 253 717 IS A RELATED FAMILY MEMBER OF JP 63-79828.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/535,000
				Filing Date	May 16, 2005
				First Named Inventor	Masakazu HATANO
				Group Art Unit	1617
				Examiner Name	Gigi Georgiana HUANG
Sheet	2	of	3	Attorney Docket Number	05318/HG

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number	Kind Code	Patentee or Applicant	Publication Date (MM-DD-YYYY)

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Country Code	Document Number	Kind Code	Patentee or Applicant	Publication Date (MM-DD-YYYY)	Translation	
							Yes	Abstract Only

OTHER DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	11	Jing-Ming DONG et al., "cAMP-induced Morphological Changes Are Counteracted by the Activated RhoA Small GTPase and the Rho Kinase ROKα*", <u>J. Biol. Chem.</u> , 273, No. 35, 22554-22562 (1998).
	12	Roser BUSCA et al., "Inhibition of Rho Is Required for cAMP-induced Melanoma Cell Differentiation," <u>Mol. Biol. Cell.</u> , 9(6), 1367-1378 (1998).
	13	Michael DIESTELHORST, "Combined therapy of Pilocarpine or Latanoprost with Timolol Versus Latanoprost Monotherapy," <u>Surv. Ophthalmology</u> , 47, Suppl 1. S155-S161 (2002).
	14	Philip P. ELLIS et al., "Aqueous Humor Pilocarpine and Timolol Levels After Instillation of the Single Drug or in Combination," <u>Invest. Ophthalmology & Visual Science</u> , 32(3), 520-522 (1991).
	15	Asahi Kasei Press Release of August 20, 2002.*
	16	CALBIOCHEM GENERAL CATALOG, 2002-2003.
	17	WAKO Bio Window, 38 March 2002.
	18	"Ryokunaisho to Ganatsu (Glaucoma and Intraocular Pressure)," <u>Ganka (Ophthalmology)</u> , No. 37.*

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE MAILED OR TRANSMITTED: April 15, 2011

* PARTIAL ENGLISH-LANGUAGE TRANSLATION ENCLOSED.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/535,000
				Filing Date	May 16, 2005
				First Named Inventor	Masakazu HATANO
				Group Art Unit	1617
				Examiner Name	Gigi Georgiana HUANG
Sheet	3	of	3	Attorney Docket Number	05318/HG

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number	Kind Code	Patentee or Applicant	Publication Date (MM-DD-YYYY)

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Country Code	Document Number	Kind Code	Patentee or Applicant	Publication Date (MM-DD-YYYY)	Translation	
							Yes	Abstract Only
	19	JP	2003-29242	A	SANTEN PHARMACEUTICAL CO., LTD.	10-15-2003	d	

OTHER DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE MAILED OR TRANSMITTED: April 15, 2011

d US 2005/0043412 IS A RELATED FAMILY MEMBER OF JP 2003-29242